CompoAtlas

5-HTP Complex

En vente sur le marché américain (selon le DSLD)

Orzax, food supplement from the US market

5-HTP Complex (Orzax), a food supplement au code-barres 860007863240, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. Doses of folates are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Orzax
Barcode
860007863240
Form
Capsule
One serving
2 capsules
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Microcrystalline Cellulose, Silicon Dioxide, Magnesium Stearate, Vegetable Capsule
Ingredient (as written, in English)CategoryPer serving
RiboflavinVitamin2.8 mg
Folic AcidVitamin400 µg
5-HydroxytryptophanAmino acid100 mg
L-TryptophanAmino acid100 mg
RhodiolaPlant100 mg

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • 5-Hydroxytryptophan
    Read the warning, when it applies and the studies cited

    5-HTP

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses (excluding weight management).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: Weight management.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Condition of application: Healthy mood balance; Fibromyalgia symptoms.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.

    Contraindications

    Condition of application: All uses.

    Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Weight management.

    Do not use if you are pregnant (HC 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 August 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Orzax

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line